Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph A Dimasi

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Nature Reviews. Drug Discovery|December 15, 2010
Competitiveness in follow-on drug R&D: a race or imitation?Joseph A DiMasi, Laura B Faden
Health Affairs (Project Hope)|May 5, 2025
Oncology Drugs: The Authors ReplyHenry Grabowski, Joseph A DiMasi, Genia Long
Pharmacoeconomics|November 30, 2002
Returns on research and development for 1990s new drug introductionsHenry Grabowski, John Vernon, Joseph A DiMasi
Health Affairs (Project Hope)|October 7, 2024
Postapproval Innovation For Oncology Drugs And The Inflation Reduction ActHenry Grabowski, Joseph A DiMasi, Genia Long
Therapeutic Innovation & Regulatory Science|September 22, 2018
The Impact of Collaborative and Risk-Sharing Innovation Approaches on Clinical and Regulatory Cycle TimesJoseph A DiMasi, Jennifer Kim, Kenneth A Getz
Health Affairs (Project Hope)|February 4, 2015
The roles of patents and research and development incentives in biopharmaceutical innovationHenry G Grabowski, Joseph A DiMasi, Genia Long
Clinical Therapeutics|May 15, 2018
Assessing the Financial Benefits of Faster Development Times: The Case of Single-source Versus Multi-vendor Outsourced Biopharmaceutical ManufacturingJoseph A DiMasi, Zachary Smith, Kenneth A Getz
Therapeutic Innovation & Regulatory Science|September 21, 2018
Analysis of Review Times for Recent 505(b)(2) ApplicationsSharon Sakai, Joseph A DiMasi, Kenneth A Getz
American Journal of Therapeutics|December 23, 2009
Private sector contributions to pharmaceutical science: thirty-five summary case historiesBenjamin Zycher, Joseph A DiMasi, Christopher-Paul Milne
Health Economics|August 6, 2009
Drug development costs when financial risk is measured using the Fama-French three-factor modelJohn A Vernon, Joseph H Golec, Joseph A Dimasi
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Nature Reviews. Drug Discovery|December 15, 2010
Competitiveness in follow-on drug R&D: a race or imitation?Joseph A DiMasi, Laura B Faden
Health Affairs (Project Hope)|May 5, 2025
Oncology Drugs: The Authors ReplyHenry Grabowski, Joseph A DiMasi, Genia Long
Pharmacoeconomics|November 30, 2002
Returns on research and development for 1990s new drug introductionsHenry Grabowski, John Vernon, Joseph A DiMasi
Health Affairs (Project Hope)|October 7, 2024
Postapproval Innovation For Oncology Drugs And The Inflation Reduction ActHenry Grabowski, Joseph A DiMasi, Genia Long
Therapeutic Innovation & Regulatory Science|September 22, 2018
The Impact of Collaborative and Risk-Sharing Innovation Approaches on Clinical and Regulatory Cycle TimesJoseph A DiMasi, Jennifer Kim, Kenneth A Getz
Health Affairs (Project Hope)|February 4, 2015
The roles of patents and research and development incentives in biopharmaceutical innovationHenry G Grabowski, Joseph A DiMasi, Genia Long
Clinical Therapeutics|May 15, 2018
Assessing the Financial Benefits of Faster Development Times: The Case of Single-source Versus Multi-vendor Outsourced Biopharmaceutical ManufacturingJoseph A DiMasi, Zachary Smith, Kenneth A Getz
Therapeutic Innovation & Regulatory Science|September 21, 2018
Analysis of Review Times for Recent 505(b)(2) ApplicationsSharon Sakai, Joseph A DiMasi, Kenneth A Getz
American Journal of Therapeutics|December 23, 2009
Private sector contributions to pharmaceutical science: thirty-five summary case historiesBenjamin Zycher, Joseph A DiMasi, Christopher-Paul Milne
Health Economics|August 6, 2009
Drug development costs when financial risk is measured using the Fama-French three-factor modelJohn A Vernon, Joseph H Golec, Joseph A Dimasi
Pageof 4